A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
| Condition | Inherited Mitochondrial Disease |
|---|---|
| Phase | Phase 3 |
| Sponsor | PTC Therapeutics |
| Status | Completed |
| Enrollment | 101 participants |
| Interventions | Vatiquinone |
| Start date | Jun 22, 2022 |
| Completion date | Apr 15, 2025 |
| Results posted | Dec 22, 2025 |
Summary
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
| Vatiquinone | 91 Participants |
|---|
Open in BENITIONS View on ClinicalTrials.gov
Other trials for this condition
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner